Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions.
Myeloma bone disease is due to bone degradation by osteoclasts, and absence of repair by bone forming osteoblasts. Recent observations suggest that the anti-myeloma drug bortezomib, a proteasome inhibitor, stimulates bone formation and may inhibit bone resorption. Here, we tested bortezomib on cultured osteoclasts in conditions mimicking the pulse treatment used in the clinic, thereby avoiding continuous proteasome inhibition and unselective toxicity. A 3 h pulse with 25 nM bortezomib followed by a 3-day culture in its absence markedly inhibited osteoclast activity as evaluated through bone resorption, TRAcP release, and RANKL-induced NF-kappaB translocation into nuclei, an event dependent on proteasomes and critical for osteoclast function. The effect on TRAcP was maximal during the first 24 h post-pulse, and then tended to subside. Importantly, applying this pulse treatment to cultured myeloma cells drastically reduced their survival. We measured next the levels of two bone resorption markers in patients during the 3 days following five and seven therapeutic bortezomib administrations, respectively. These levels decreased significantly already 1-2 days after injection, and then increased, showing temporary inhibition of osteoclast activity and paralleling the in vitro effect on TRAcP. Our study demonstrates a direct inhibition of osteoclasts by bortezomib in conditions relevant to treatment of myeloma.
Boissy
P
P
Department of Clinical Cell Biology and Hematology Unit, IRS-CSFU, Southern Denmark University, Vejle Hospital, Vejle, Denmark.
Andersen
T L
TL
Lund
T
T
Kupisiewicz
K
K
Plesner
T
T
Delaissé
J M
JM
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000494:pharmacology; D001862:Bone Resorption / Q000188:drug therapy* / Q000378:metabolism; D001897:Boronic Acids / Q000008:administration & dosage* / Q000494:pharmacology; D000069286:Bortezomib; D002467:Cell Nucleus / Q000378:metabolism; D049109:Cell Proliferation; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D010006:Osteoblasts / Q000187:drug effects; D010010:Osteoclasts / Q000187:drug effects* / Q000378:metabolism; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism; D061988:Proteasome Inhibitors; D020551:Pulse Therapy, Drug; D011719:Pyrazines / Q000008:administration & dosage* / Q000494:pharmacology; D053245:RANK Ligand / Q000494:pharmacology; D012333:RNA, Messenger / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015398:Signal Transduction; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D001897:Boronic Acids; D016328:NF-kappa B; D061988:Proteasome Inhibitors; D011719:Pyrazines; D053245:RANK Ligand; D012333:RNA, Messenger; D000069286:Bortezomib; D046988:Proteasome Endopeptidase Complex